Guggenheim reiterates buy on Johnson & Johnson, maintains $270 target

0 min read | Published on 17 Jul 2026, 07:02 PM |Updated on 17 Jul 2026, 07:02 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Guggenheim analyst Vamil Divan has reiterated a Buy rating on Johnson & Johnson (NYSE: JNJ) and maintained a price target of $270, indicating confidence in the stock's future performance.

*this image is generated using AI for illustrative purposes only.

Guggenheim analyst Vamil Divan has reaffirmed a Buy rating on Johnson & Johnson (NYSE: JNJ), maintaining a price target of $270. The reiteration underscores the firm's confidence in the healthcare company's stock performance.

Analyst Rating and Price Target

The research note from Guggenheim highlights the following key details:

Analyst	Rating	Price Target
Vamil Divan	Buy	$270

Johnson & Johnson continues to be viewed favorably by Guggenheim, with the $270 target suggesting potential upside from current trading levels.

What specific catalysts does Guggenheim expect to drive Johnson & Johnson's stock to the $270 price target?

How might recent developments in Johnson & Johnson's pharmaceutical pipeline impact future earnings growth?

What are the potential risks, such as legal challenges or competitive pressures, that could hinder JNJ's upside?

Raymond James raises Johnson & Johnson price target to $265

0 min read | Published on 17 Jul 2026, 01:00 AM |Updated on 17 Jul 2026, 01:00 AM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Raymond James analyst Jayson Bedford maintained an Outperform rating on Johnson & Johnson and raised the price target to $265 from $258, signaling confidence in the stock's potential.

*this image is generated using AI for illustrative purposes only.

Raymond James analyst Jayson Bedford has maintained an Outperform rating on Johnson & Johnson (NYSE:JNJ) while increasing the price target to $265 from $258. The adjustment reflects a revised valuation outlook for the healthcare conglomerate.

The rating affirmation and target increase highlight the firm's continued confidence in the company's performance trajectory. Investors holding Johnson & Johnson shares may see this revision as an indicator of potential upside.